Use of a gonadotrophin-releasing hormone vaccine in headshaking horses.
Authors: Pickles K J, Berger J, Davies R, Roser J, Madigan J E
Journal: The Veterinary record
Summary
# Gonadotrophin-Releasing Hormone Vaccination for Equine Headshaking: Limited Clinical Efficacy Despite Hormonal Changes Headshaking remains a challenging idiopathic condition in equine practice, prompting investigation of novel therapeutic approaches including gonadotrophin-releasing hormone (GnRH) immunisation, which theoretically reduces circulating reproductive hormones that may contribute to trigeminal neuropathy. Fifteen geldings received two doses of a commercial GnRH vaccine four weeks apart, with owners documenting seven common headshaking behaviours using visual analogue scales at baseline and multiple timepoints over 20 weeks, whilst serum luteinising hormone and follicle-stimulating hormone concentrations were measured to confirm vaccine efficacy. Vaccination successfully suppressed both LH (P=0.008) and FSH (P=0.03) concentrations, yet objective behavioural scoring revealed no significant reduction in headshaking episodes, despite approximately one-third of owners reporting subjective improvement—likely reflecting placebo effect or response bias. Adverse effects occurred in 27 per cent of treated horses, including a severe presumed immune-mediated myositis in one gelding, raising safety concerns that outweigh the limited and subjective clinical benefits. For practitioners considering GnRH vaccination as a headshaking treatment, current evidence does not support routine use; whilst the vaccine reliably modulates reproductive hormones, the lack of objective clinical improvement combined with the risk of serious vaccination reactions suggests exploring alternative diagnostic and therapeutic avenues remains prudent.
Read the full abstract on PubMed
Practical Takeaways
- •GnRH vaccine is ineffective for treating headshaking in horses based on objective behavioural scoring, despite owner-reported subjective improvements that may reflect placebo effect
- •Significant adverse reaction rate (27%) including severe myositis makes this treatment option carry considerable risk for clinical use
- •Practitioners should be cautious about recommending this vaccine for headshaking cases given lack of objective efficacy and safety concerns
Key Findings
- •GnRH vaccination significantly reduced serum LH (P=0.008) and FSH (P=0.03) concentrations
- •Despite hormonal changes, serial scoring showed no significant reduction in headshaking behaviours following vaccination
- •Approximately one-third of owners reported subjective improvement in headshaking symptoms
- •Vaccination reactions occurred in 4 of 15 horses (27%), including one case of severe immune-mediated myositis